These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 10102489)

  • 1. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A; Roisenberg I
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.
    Pascual V; Capra JD
    J Clin Invest; 1996 Mar; 97(6):1357-8. PubMed ID: 8617864
    [No Abstract]   [Full Text] [Related]  

  • 3. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Yee TT; Lee CA
    Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768
    [No Abstract]   [Full Text] [Related]  

  • 4. Disappearance of FVIII inhibitors in a severe hemophilia A neonate after steroid treatment correlated with a cytokine shift toward a T-helper 2 pattern.
    Vianello F; Zanon E; Zerbinati P; Innella B; Girolami A
    Haematologica; 2000 Oct; 85(10):1114-5. PubMed ID: 11025617
    [No Abstract]   [Full Text] [Related]  

  • 5. Inhibitor development in a multitransfused patient with severe haemophilia A.
    van den Berg HM; Roosendaal G; Voorberg J; Mauser-Bunschoten EP
    Thromb Haemost; 1999 Jul; 82(1):151-2. PubMed ID: 10456472
    [No Abstract]   [Full Text] [Related]  

  • 6. Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.
    Penner JA
    Haemophilia; 2001 Jan; 7(1):103-8. PubMed ID: 11136390
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine.
    Ambriz Fernandez R; Quintana Gonzalez S; Martinez Murillo C; Dominguez Garcia V; Rodriguez Moyado H; Collazo Jaloma J
    Arch Med Res; 1996; 27(1):15-8. PubMed ID: 8867361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?
    Clere AS; Diaz I; Lebreton A; Lavigne-Lissalde G; Schved JF; Biron-Andreani C
    Haemophilia; 2014 Nov; 20(6):e406-8. PubMed ID: 25311419
    [No Abstract]   [Full Text] [Related]  

  • 9. Epidemiology of inhibitors in haemophilia A.
    Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Güngör T; Kornhuber B
    Vox Sang; 1996; 70 Suppl 1():2-8. PubMed ID: 8869461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
    Monahan PE; Aledort LM;
    Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of inhibitors from recombinant factor VIII: a quarter of a century to reach the conclusion.
    Burnouf T; Strengers PF
    J Thromb Haemost; 2016 Oct; 14(10):2073-2074. PubMed ID: 27496669
    [No Abstract]   [Full Text] [Related]  

  • 12. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.
    van den Brink EN; Timmermans SM; Turenhout EA; Bank CM; Fijnvandraat K; Voorberg J; Peters M
    Thromb Haemost; 1999 May; 81(5):723-6. PubMed ID: 10365744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors.
    Dasgupta S; Navarrete AM; Delignat S; Wootla B; Andre S; Nagaraja V; Lacroix-Desmazes S; Kaveri SV
    Immunol Lett; 2007 May; 110(1):23-8. PubMed ID: 17467813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Poly-electrolyte fractionated porcine factor VIII in the treatment of hemophilia A].
    Ferencz T; Skopál J; Csáki C; Laczkó M; Schuler D; Borsi J
    Orv Hetil; 1993 Dec; 134(52):2873-5. PubMed ID: 8272354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII inhibitors, natural history and management.
    Allain JP
    Southeast Asian J Trop Med Public Health; 1979 Jun; 10(2):241-2. PubMed ID: 524148
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 17. Postpartum acquired factor VIII inhibitors.
    Franchini M
    Am J Hematol; 2006 Oct; 81(10):768-73. PubMed ID: 16868941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemophilia treatment. Side effects during immune tolerance induction.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Haematologica; 2000 Oct; 85(10 Suppl):75-7. PubMed ID: 11187878
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to factor VIII in hemophilia A patients.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.